Lys-Pro-Val tripeptide derived from alpha-MSH
PRODUCT PROFILE
KPV
Price range: £27.47 through £29.99
KPV is lys-pro-val tripeptide derived from alpha-msh. Researchers examine it in relation to inflammatory signalling in intestinal, skin and immune-cell models.
Why it is distinct
A minimal anti-inflammatory alpha-MSH fragment rather than an antimicrobial peptide such as LL-37.
- Evidence stagePreclinical
- AvailabilityAvailable · 20 in stock
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
KPV is lys-pro-val tripeptide derived from alpha-msh. Researchers examine it in relation to inflammatory signalling in intestinal, skin and immune-cell models.
Research focus+
Researchers study whether it can calm inflammatory activity in gut, skin and immune-cell models. Most evidence is still from laboratory or animal research.
How the mechanism differs+
Studied preclinically for modulation of NF-kB-linked inflammatory responses without reproducing alpha-MSH pigmentation signalling.
Evidence and limitations+
Mostly cell and animal evidence; controlled human evidence for isolated KPV remains very limited.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can calm inflammatory activity in gut, skin and immune-cell models. Most evidence is still from laboratory or animal research.
Studied preclinically for modulation of NF-kB-linked inflammatory responses without reproducing alpha-MSH pigmentation signalling.
A minimal anti-inflammatory alpha-MSH fragment rather than an antimicrobial peptide such as LL-37.
Mostly cell and animal evidence; controlled human evidence for isolated KPV remains very limited.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Bronchogen
£46.0020 mgBatch file pendingAirway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.
UnavailableAsk about availability -
Early human evidence
LL-37
£59.005 mgBatch file pendingDirect antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
UnavailableAsk about availability -
Established
Thymosin Alpha-1
£69.0010 mgBatch file pendingAn immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
UnavailableAsk about availability -
Experimental
Vilon
£46.0020 mgBatch file pendingA minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
UnavailableAsk about availability